Board of Directors admin
The Blueberry Board of Directors
Dr John RiddenChief Executive Officer
John has almost 20 years of experience in both large and small BioPharma progressing a number of projects through preclinical research to candidate drug nomination. Following a DPhil in Clinical Biochemistry at Oxford John went on to complete a Postdoctoral position in Peter Parker’s lab at the Institute for Cancer Research working on identifying and characterising a new class of kinases involved in cancer. John then worked for a small biotech company working in oncology and dermatology therapy areas and from here moved to Pfizer for 7 years where he worked on a number of drug discovery projects in Cardiovascular and Tissue Repair research areas. Subsequently he moved to AstraZeneca where he worked for 11 years at a senior leadership level in target identification and translational research supporting Oncology, Respiratory and Inflammation, and Cardiovascular research areas.
Dr Mike DaviesChief Medical Officer
Mike graduated from Edinburgh University Medical School in 1985 and has over 18 years of pharma experience in large, medium and small BioPharma in EU and US. Mike worked for 5 years at Pfizer where he led the early clinical development in Tissue Repair and Cardiovascular projects. He then moved to biotech in Manchester Incubator where he again lead the clinical development in anti-scarring and wound healing compounds at Renovo. Mike progressed into consultancy and worked for dermatology companies in US and EU. He also spent 18 months as Medical Director at AstraZeneca. From 2005, Mike worked as Vice President at Shire Pharmaceuticals for 4 years where he lead the late phase development and EU registration of Dynepo™, Fosrenol®, and Lialda™/Mezavant®. For the last 3 years Mike has been Vice President of the Global Strategic Drug Development Unit at Quintiles Transnational where he covers all aspects of preclinical and clinical drug development and scientific/medical portfolio analysis, including portfolio management, regulatory and pharmacogenetics expertise, with a specialist interest in translational medicine
Tony SedgwickAdvisor to the Board
Tony Sedgwick was previously Chief Executive Officer of the UK biotech company Daniolabs Ltd. and the UK biotech company Cambridge Biotechnology Ltd., both companies being successfully exited by trade sale. Tony has been an executive and non-executive of a large number of life science companies in the UK and continental Europe. Between 1986 and 2002 Tony worked for Roche in several senior management roles, latterly as Global Head of Clinical Operations and UK Development Director.
Rita DobmeyerBoard Member
Dr. Rita Dobmeyer is a graduate of the University of Kaiserslautern, Germany with degrees in Biology. She got a PHD at the German Cancer research Center, Heidelberg in infectiology and worked with the Nobel Prize award winner Luc Montagnier. Prior to founding GALENUS GmbH she was Director European Consulting and Client Relations for Parexel GmbH in Berlin Germany. Previous to Parexel, Dr. Dobmeyer was Director of Phase IV Clinical Services and Postmarketing Surveillance at IMS Health, a founding member of IBAH (CRO) and has extensive clinical trial experience in diverse companies. Rita was founder of 8 companies and is networked with investors and key opinion leaders around the world.
Dr. Rita Dobmeyer is an accomplished researcher and the author/co-author of more than 50 articles and several book chapters, has been a speaker for several international conferences, has consulted for several university-based drug development companies and is a board member of several foundations and companies.
Andrew KayChairman of the Board
Mr. Andrew Kay brings more than 30 years of commercial and leadership experience in the pharmaceutical sector, latest as CEO of Algeta ASA. During Mr. Kay’s leadership, Algeta’s lead product, Xofigo, was approved by the FDA and EMA for the treatment of bone metastases in castration resistant prostate cancer patients, followed by a strong commercial launch. In February 2014, Algeta was acquired by its partner Bayer AG for USD 2.9 billion. Mr. Kay’s previous assignments include Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and several other senior commercial positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots.